Imagine a breast scan that works like a radar instead of an X-ray. It uses safe microwave signals to find tumors without squeezing the breast or using radiation. This makes it much easier to spot cancer in women with dense breast tissue, where traditional mammograms often struggle.
Traditional mammography is limited by breast density and causes patient discomfort due to compression and radiation. This leads to missed detections in younger women and lower screening participation rates.
A microwave-based imaging device (MammoWave), AI-supported analysis software, and a patient-facing mobile application.
If you are a diagnostic equipment provider dealing with the limitations of X-ray density and patient discomfort — this project developed the MammoWave device that uses non-ionizing microwave signals to achieve sensitivity >90% and specificity >95%. It removes the need for breast compression, making screening more female-friendly.
If you are a software developer dealing with the difficulty of detecting early-stage lesions in dense tissue — this project developed machine-learning-supported software to analyze microwave signals. This AI helps overcome class imbalance in screening data to improve detection accuracy.
If you are a health system operator dealing with low participation in screening and high costs of MRI/Ultrasound — this project developed a screening technique that requires no specialized infrastructure. It aims to extend screening to 98 million women aged 20-49 in Europe.
Based on available project data, specific pricing is not mentioned, but the project includes a Health Technology Assessment to explore economic and organizational aspects.
Yes, the project is conducting a large multicentric clinical investigation involving 10,000 study participants to prove its performance in real-world screening conditions.
Based on available project data, the technology MammoWave was developed by UBT; however, specific licensing terms for the consortium are not detailed.
The project is generating clinical and technical evidence to ensure the device is recommended by policy makers for use in national and regional screening programs.
The examination requires no specialized infrastructure, making it easier to integrate into existing healthcare settings compared to MRI or mammography.
The consortium is lean and balanced with 7 partners across 4 countries. It features a 29% industry ratio (2 industrial partners), ensuring that the research from the 2 universities and 1 research center is grounded in commercial viability. The presence of 2 SMEs suggests a focus on agile development and rapid technology transfer.
Contact Fondazione Toscana Life Sciences in Italy
Contact us to explore licensing opportunities for MammoWave AI algorithms.
